Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for CMV Prevention in Japanese Kidney Transplant Recipients
NCT04129398Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of letermovir in cytomegalovirus infection (CMV), sponsored by Merck & Co.. Started Dec 2019; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT04129398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129398.